Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity

BACKGROUND: People with multiple sclerosis (pwMS) on anti-CD20 therapies (aCD20) and fingolimod have shown inadequate humoral responses to COVID-19 vaccines. OBJECTIVE: The objective of the study was to pilot larger studies by demonstrating the safety and comparing the immunogenicity of different ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedaghat, Nahad, Etemadifar, Masoud, Lotfi, Noushin, Sayahi, Farnaz, Chitsaz, Ahmad, Salari, Mehri, Ghasemi Movaghar, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989190/
https://www.ncbi.nlm.nih.gov/pubmed/36895555
http://dx.doi.org/10.3389/fimmu.2023.952911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989190/
https://www.ncbi.nlm.nih.gov/pubmed/36895555
http://dx.doi.org/10.3389/fimmu.2023.952911

Ejemplares similares